Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05EQG
|
||||
| Former ID |
DIB018414
|
||||
| Drug Name |
[3H]spiperone
|
||||
| Synonyms |
[3H]-spiperone
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [540262] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H26FN3O2
|
||||
| InChI |
InChI=1S/C23H26FN3O2/c24-19-10-8-18(9-11-19)21(28)7-4-14-26-15-12-23(13-16-26)22(29)25-17-27(23)20-5-2-1-3-6-20/h1-3,5-6,8-11H,4,7,12-17H2,(H,25,29)
|
||||
| InChIKey |
DKGZKTPJOSAWFA-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | D(3) dopamine receptor | Target Info | Antagonist | [525818] | |
| D(4) dopamine receptor | Target Info | Antagonist | [533735] | ||
| D(2) dopamine receptor | Target Info | Antagonist | [525818] | ||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| References | |||||
| Ref 525818 | Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br J Pharmacol. 2000 Jul;130(5):1045-59. | ||||
| Ref 533735 | Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors. Neurosci Lett. 1995 Feb 17;186(2-3):145-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.